A UPLC-MS/MS method for quantification of a novel doxorubicin conjugation prodrug in tumor cells

Nan ZHENG,Xing WANG,Yao-qi WANG,Guo-bing XU,Hua ZHANG,Wen-bing DAI,Bing HE,Qiang ZHANG,Xue-qing WANG
DOI: https://doi.org/10.16438/j.0513-4870.2017-1031
2018-01-01
Abstract:In this study,we developed a rapid and sensitive ultra high-performance liquid chromatographytandem mass spectrometry (UPLC-MS/MS) method to detect a sulfide bond doxorubicin conjugation prodrug (DOX-S-DOX) in human breast cancer tumor cells (MCF-7).The samples were prepared by acetonitrile precipitation using daunorubicin as internal standard (IS).A reversed phase C18 analytical column (Agilent Eclipse plus C18 RRHD 1.8 μm,2.1 mm × 50 mm) was utilized to separate the samples under gradient elution conditions.Mobile phase was a mixture of 0.1% formic acid in water and methanol at a flow rate of 0.4 mL ·min-1.The analysis was conducted on the mass spectrometer using an electrospray interface (ESI) in the positive ionization model.The calibration range was 20.0-400 ng·mL-1 with the correlation coefficients (r2) ≥ 0.99.The interand intra-assay precision (relative standard deviation,RSD%) of quality control samples was within 3.77%-8.35% and relative error (RE%) for accuracy was between-2.04% and 2.62%.Recovery (97.67%-104.2%) and matrix effect (104.8%-113.9%) were consistent,precise,and reproducible at different quality control levels in accordance with FDA guidance.The assay was successfully used in the cellular pharmacokinetics study of DOX-S-DOX,which may provide a clue to explore analytical methods of other prodrug forms of DOX.
What problem does this paper attempt to address?